Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays

Safety aspects have become an outstanding issue in the process of drug discovery and development. Until 15 years ago safety aspects were addressed by pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Vogel, H. Gerhard (Επιμελητής έκδοσης), Maas, Jochen (Επιμελητής έκδοσης), Hock, Franz J. (Επιμελητής έκδοσης), Mayer, Dieter (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2013.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04092nam a22004455i 4500
001 978-3-642-25240-2
003 DE-He213
005 20151204174805.0
007 cr nn 008mamaa
008 130305s2013 gw | s |||| 0|eng d
020 |a 9783642252402  |9 978-3-642-25240-2 
024 7 |a 10.1007/978-3-642-25240-2  |2 doi 
040 |d GrThAP 
050 4 |a RM1-950 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
082 0 4 |a 615  |2 23 
245 1 0 |a Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays  |h [electronic resource] /  |c edited by H. Gerhard Vogel, Jochen Maas, Franz J. Hock, Dieter Mayer. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg :  |b Imprint: Springer,  |c 2013. 
300 |a 243 illus. eReference.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a From the contents: General Introduction: Safety Pharmacology -- Safety Pharmacokinetics -- Safety Toxicology. 
520 |a Safety aspects have become an outstanding issue in the process of drug discovery and development. Until 15 years ago safety aspects were addressed by pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound. These tests were followed by pharmacokinetic studies, which were mainly aimed at confirming of a suitable half-life time and at oral activity. Safety aspects relied mostly on toxicity studies, which however gave information on changes of organ structure rather than on organ function. Toxicological and pharmacokinetic studies were adapted to the progress of studies in clinical pharmacology and clinical trails. But the success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. A change of strategy was therefore adopted, involving the following changes: -          Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization). -          The term "Safety Pharmacology" was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group. Easily accessible and the most informative tests now have to be selected. -          Exposure of a drug to the body by pharmacokinetic studies on absorption, distribution, metabolism and excretion has to be investigated at an early stage of development and can contribute to the selection of a compound for development. Toxicology experienced major achievements by the introduction of new methods, e.g., in silico methods, toxicogenomics and toxicoproteomics. The book is a landmark in the continuously changing world of drugs. As such it is important reading for many groups: not only for all students of pharmacology and toxicology but also for physicians, especially those involved in clinical trials of drugs, and for pharmacists who have to know the safety requirements of drugs. The book is absolutely essential for scientists and managers in the pharmaceutical industry who are involved in drug finding, drug development and decision making in the development process. In particular, the book will be of use for government institutions and committees working on official guidelines for drug evaluation worldwide. 
650 0 |a Medicine. 
650 0 |a Pharmacology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Pharmacology/Toxicology. 
700 1 |a Vogel, H. Gerhard.  |e editor. 
700 1 |a Maas, Jochen.  |e editor. 
700 1 |a Hock, Franz J.  |e editor. 
700 1 |a Mayer, Dieter.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783642252396 
856 4 0 |u http://dx.doi.org/10.1007/978-3-642-25240-2  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)